326030:KRXSK Biopharmaceuticals Co., Ltd. Analysis

SK Biopharmaceuticals is posting spectacular top‑line momentum, with revenue surging 57.8% YoY and ultra‑high gross margins of 94% that translate into a robust operating margin of nearly 40% and a ROE above 44%. Cash is abundant – KRW 310.9 bn on hand versus KRW 49.9 bn of debt – and free cash flow remains healthy, underscoring a solid balance sheet despite a debt‑to‑equity ratio that appears elevated on a book‑value basis. However, the market is pricing the stock at KRW 88,100, more than double the DCF‑derived fair value of KRW 38,331, implying a steep downside of roughly 56%. The technical picture is equally bearish: the price sits below the 20‑day (95,050) and 50‑day (97,776) SMAs, the MACD is in a bearish divergence, RSI is hovering at 36 (approaching oversold), and the stock is flirting with its support at KRW 87,300 while facing resistance near KRW 106,200. Volume is rising, but volatility is high at 36% over the past month, and the Fear‑Greed Index signals “Extreme Greed,” suggesting speculative pressure may be inflating the price.
Given the strong growth fundamentals and an extensive pipeline of CNS‑focused drugs, the long‑run narrative remains compelling. Yet the current valuation gap, combined with sector‑specific regulatory uncertainty and a bearish short‑term technical setup, points to a near‑term correction risk. Investors should weigh the upside from pipeline milestones against the immediate downside pressure from overvaluation and market sentiment.